Literature DB >> 16204151

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.

Linda M Scott, Peter J Campbell, E Joanna Baxter, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R Stratton, P Andrew Futreal, Anthony R Green.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16204151     DOI： 10.1182/blood-2005-05-2087

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  45 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  JAK2(V617F): Prevalence in a large Chinese hospital population.

Authors:  Xuesong Xu; Qi Zhang; Jian Luo; Shu Xing; Qingshan Li; Sanford B Krantz; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

3.  Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors:  S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal:  Ir J Med Sci       Date:  2007-04-18       Impact factor: 1.568

4.  Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Authors:  Monika Ribeiro Mello de Conchon; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Pedro Enrique Dorlhiac-Llacer; Dalton de Alencar Fischer Chamone; Israel Bendit
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

5.  Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.

Authors:  Zhe Li; Mingjiang Xu; Shu Xing; Wanting Tina Ho; Takefumi Ishii; Qingshan Li; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

6.  Absence of JAK2 V617F mutation in thalassemia intermedia patients.

Authors:  Ali Taher; Dina Shammaa; Ali Bazarbachi; Doha Itani; Ghazi Zaatari; Layal Greige; Zaher K Otrock; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

Review 7.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

8.  Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.

Authors:  Zhe Li; Shu Xing; Shaofeng Wang; Wanting Tina Ho; Zhizhuang Joe Zhao
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

9.  The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors:  Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

10.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.